CJC-1295 (No DAC) vs Tesamorelin
Two engineering answers to the same problem — native GHRH is destroyed within minutes — reached from opposite directions.
How they actually differ
Tesamorelin keeps the full 44-residue GHRH sequence and caps its front end to block the protease. CJC-1295 without DAC truncates to the first 29 residues and rebuilds the same resistance through four internal substitutions. Cap-the-end versus rewrite-the-middle. Both dissolve in plain water and are refrigerated after mixing; both have amphipathic coils that foam if shaken, so both ask for a gentle swirl.
CJC-1295 (No DAC) — origin
CJC-1295 without DAC is the first 29 residues of growth-hormone-releasing hormone carrying four stabilising substitutions (D-Ala2, Gln8, Ala15, Leu27) that resist DPP-4 cleavage. Omitting the Drug Affinity Complex — the albumin-binding element of the DAC version — gives it a short half-life, which is the property researchers study it for.
Tesamorelin — origin
Tesamorelin is the complete 44-amino-acid sequence of human growth hormone-releasing hormone with a trans-3-hexenoic acid group attached at the N-terminus. That modification exists for one reason: native GHRH is cleaved almost immediately by dipeptidyl peptidase-4 at the N-terminal end, and the hexenoyl group blocks that cleavage.
CJC-1295 (No DAC) research themes
Studied for prompting growth-hormone release in short, physiological pulses via the GHRH receptor.
The four substitutions are studied for extending the molecule beyond the minutes-long survival of native GHRH.
Frequently studied alongside ghrelin-receptor secretagogues such as Ipamorelin, which recruit a second GH-release pathway.
Tesamorelin research themes
Full-length GHRH activity with DPP-4 resistance conferred by the N-terminal modification.
The most distinctive endpoint in its research literature.
Studied for effects on endogenous GH secretion patterns rather than direct GH substitution.
Investigated alongside body-composition endpoints in metabolic research.
CJC-1295 (No DAC) handling
- Reach room temperature before opening.
- Swirl to dissolve; do not shake or vortex — foam indicates interfacial stress on the helix.
- Aliquot and refrigerate; never re-freeze reconstituted solution.
Tesamorelin handling
- Allow several minutes for dissolution; do not accelerate with agitation or heat.
- Swirl gently — long chains aggregate at interfaces.
- Do not freeze reconstituted solution.
Both third-party tested
Every Popular Peptides batch of CJC-1295 (No DAC) and Tesamorelin is independently tested by HPLC and LC-MS with a published Certificate of Analysis. Enter a lot number to pull the COA for a specific vial.
CJC-1295 (No DAC) reference
Related comparisons
CJC-1295 (No DAC) and Tesamorelin are supplied strictly as research chemicals for in-vitro laboratory and research use only. They are not intended for human or animal consumption, diagnostic, or therapeutic use. This comparison summarizes published preclinical literature and laboratory handling data; it is not medical advice, not a claim of efficacy, and not usage guidance.